Download PDF
Thromb Haemost 1995; 74(02): 673-679
DOI: 10.1055/s-0038-1649796
Original Article
Coagulation
Schattauer GmbH Stuttgart

Comparison of Immunological and Functional Assays for Measurement of Soluble Fibrin

C E Dempfle
The University of Heidelberg, Klinikum Mannheim, Ist Dept. of Medicine, Mannheim, Germany
,
S A Pfitzner
The University of Heidelberg, Klinikum Mannheim, Ist Dept. of Medicine, Mannheim, Germany
,
M Dollman
The University of Heidelberg, Klinikum Mannheim, Ist Dept. of Medicine, Mannheim, Germany
,
K Huck
*   The University of Heidelberg, Klinikum Mannheim, IInd Dept. of Medicine, Mannheim, Germany
,
G Stehle
The University of Heidelberg, Klinikum Mannheim, Ist Dept. of Medicine, Mannheim, Germany
,
D L Heene
The University of Heidelberg, Klinikum Mannheim, Ist Dept. of Medicine, Mannheim, Germany
› Author Affiliations
Further Information

Publication History

Received 28 October 1994

Accepted after resubmission 06 March 1995

Publication Date:
04 September 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Various assays have been developed for quantitation of soluble fibrin or fibrin monomer in clinical plasma samples, since this parameter directly reflects in vivo thrombin action on fibrinogen. Using plasma samples from healthy blood donors, patients with cerebral ischemic insult, patients with septicemia, and patients with venous thrombosis, we compared two immunologic tests using monoclonal antibodies against fibrin-specific neo-epitopes, and two functional tests based on the cofactor activity of soluble fibrin complexes in tPA-induced plasminogen activation. Test A (Enzymun®-Test FM) showed the best discriminating power among normal range and pathological samples. Test B (Fibrinostika® soluble fibrin) clearly separated normal range from pathological samples, but failed to discriminate among samples from patients with low grade coagulation activation in septicemia, and massive activation in venous thrombosis. Functional test C (Fibrin monomer test Behring) displayed good discriminating power between normal and pathological range samples, and correlated with test A (r = 0.61), whereas assay D (Coa-Set® Fibrin monomer) showed little discriminating power at values below 10 μg/ml and little correlation with other assays. Standardization of assays will require further characterization of analytes detected.

 

  • References

  • 1 Bettelheim FR, Bailey K. The products of the action of thrombin on fibrinogen. Biochim Biophys Acta 1952; 9: 578-579
    CrossrefPubMedGoogle Scholar
  • 2 Lorand L. Fibrino-peptide. Biochem J 1952; 52: 200-203
    CrossrefPubMedGoogle Scholar
  • 3 Laudano AP, Cottrell BA, Doolittle RF. Synthetic peptides modeled on fibrin polymerization sites. Ann N Y Acad Sci 1983; 408: 315-329
    CrossrefPubMedGoogle Scholar
  • 4 Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980; 77: 1374-1378
    CrossrefPubMedGoogle Scholar
  • 5 Weisel JW. Fibrin assembly Lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J 1986; 50: 1079-1093
    CrossrefPubMedGoogle Scholar
  • 6 Hafter R, von Hugo R, Baumgärtner M, Hiller FK, Graeff H. Temperature dependent dissociation of soluble fibrin monomer complexes demonstrated by agarose gel filtration. Thromb Res 1980; 20: 325-333
    CrossrefPubMedGoogle Scholar
  • 7 Muller Berghaus G, Mahn I, Krell W. Formation and dissociation of soluble fibrin complexes in plasma at 20° C and at 37° C. Thromb Res 1979; 14: 561-572
    CrossrefPubMedGoogle Scholar
  • 8 Preissner KT, Rotker J, Selmayr E, Fasold H, Muller Berghaus G. Influence of fibrinogen on fibrin polymerization. Ultracentrifugation studies Biochim Biophys Acta 1985; 829: 358-364
    CrossrefPubMedGoogle Scholar
  • 9 Rotker J, Preissner KT, Muller Berghaus G. Soluble fibrin consists of fibrin oligomers of heterogeneous distribution. Eur J Biochem 1986; 155: 583-588
    CrossrefPubMedGoogle Scholar
  • 10 Heene DL, Matthias FR. Adsorption of fibrinogen derivatives on insolubilized fibrinogen and fibrinmonomer. Thromb Res 1973; 2: 137-154
    CrossrefPubMedGoogle Scholar
  • 11 Matthias FR, Heene DL, Konradi E. Behavior of fibrinogen and fibrinogen degradation products towards insolubilized fibrinogen and fibrin monomer. Thromb Res 1973; 3: 657-64
    CrossrefPubMedGoogle Scholar
  • 12 Selmayr E, Mahn I, Muller Berghaus G. Crosslinking of soluble fibrin and fibrinogen. Thromb Res 1985; 39: 467-474
    CrossrefPubMedGoogle Scholar
  • 13 Pacella BL J, Hui KY, Haber E, Matsueda GR. Induction of fibrin-specific antibodies by immunization with synthetic peptides that correspond to amino termini of thrombin cleavage sites. Mol Immunol 1983; 20: 521-527
    CrossrefPubMedGoogle Scholar
  • 14 Scheefers Borchel U, Muller Berghaus G, Fuhge P, Eberle R, Heimburger N. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci USA 1985; 82: 7091-7095
    CrossrefPubMedGoogle Scholar
  • 15 Schielen WJ, Voskuilen M, Adams PJ, Tesser GI, Nieuwenhuizen W. Structural requirements of fibrinogen A alpha-(148-160) for the enhancement of the rate of plasminogen activation by tPA. Blood Coagul Fibrinolysis 1990; 1: 521-524
    CrossrefPubMedGoogle Scholar
  • 16 Schielen WJ, Adams HP, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence A alpha-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen. Blood Coagul Fibrinolysis 1991; 2: 465-470
    CrossrefPubMedGoogle Scholar
  • 17 Mao SJ, Rechtin AE, Krstenansky JL, Jackson RL. Characterization of a monoclonal antibody specific to the amino terminus of the alpha-chain of human fibrin. Thromb Haemost 1990; 63: 445-448
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Dempfle CE, Dollman M, Lill H, Puzzovio D, Dessauer A, Heene DL. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site ‘A’: effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN. Blood Coagul Fibrinolysis 1993; 4: 79-86
    CrossrefPubMedGoogle Scholar
  • 19 Lill H, Spannagl M, Trauner A, Schramm W, Schuller D, Ofenloch Haehnle B, Draeger B, Naser W, Dessauer A. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo. Blood Coagul Fibrinolysis 1993; 4: 97-102
    CrossrefPubMedGoogle Scholar
  • 20 Schielen WJ, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence A alpha-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86: 8951-8954
    CrossrefPubMedGoogle Scholar
  • 21 Halvorsen S, Skjonsberg OH, Ruyter R, Godal HC. Comparison of methods for detecting soluble fibrin in plasma. An in vitro study Thromb Res 1990; 57: 489-497
    CrossrefPubMedGoogle Scholar
  • 22 Halvorsen S, Skjonsberg OH, Godal HC. Comparison of methods for detecting soluble fibrin in plasma from patients with venous thromboembolism. Thromb Res 1991; 61: 341-348
    CrossrefPubMedGoogle Scholar
  • 23 Lane DA, Siodlak M, Thompson E, Allen Mersh TG. Clearance of human desaminotyrosyl fibrinopeptide A from the rat circulation: role of kidney and proteolytic enzymes. Thromb Res 1982; 26: 73-82
    CrossrefPubMedGoogle Scholar
  • 24 Godal HC, Kierulf P. Precipitation of fibrinogen-derived material by protamine. Scand J Haematol Suppl 1971; 13: 163-164
    PubMedGoogle Scholar
  • 25 Wieding JU, Eisinger G, Kostering H. Diagnosis of disseminated intravascular coagulation: the value of soluble fibrin, D-dimers and fibrin(ogen) split products. Klin Wochenschr 1989; 67: 764-773
    CrossrefPubMedGoogle Scholar
  • 26 Wieding JU, Hosius C. Determination of soluble fibrin: a comparison of four different methods. Tliromb Res 1992; 05: 745-756
    PubMedGoogle Scholar
  • 27 Gurewich V, Hulchison L. Detection of intravascular coagulation by a serial dilution protamine sulphate test. Ann Intern Med 1971; 75: 895-902
    PubMedGoogle Scholar
  • 28 Niewiarowski S, Gurewieh V. Laboratory identification of intravascular coagulation. J Lab Cin Med 1971; 77: 665-676
    PubMedGoogle Scholar
  • 29 Wieding JU, Eisinger G, Kästering H. Determination of soluble fibrin by turbidimetry of the prolamine sulphate paraeoagulation. Excerpta mediea 1987 745: 187-190
    PubMedGoogle Scholar
  • 30 Ochler G, Klaus H, Stotzer KE, Spanuth L. Detection of soluble fibrin monomer complexes. Comparison of a haemagglutination assay with the ethanol gelation test Folia Haematol Leipz 1988; 115: 278-283
    PubMedGoogle Scholar
  • 31 Laudano AP, Doolittle RE. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites and species differences Biochemistry 1980; 19: 1013-1019
    CrossrefPubMedGoogle Scholar
  • 32 Nieuwenhuizen W, Schielen WJ, Yonekawa O, Tesser G, Voskuilen M. Studies on the localization and accessibility of sites in fibrin which are involved in the acceleration of the activation of plasminogen by tissue-type plasminogen activator. Adv Exp Med Biol 1990; 281: 83-91
    PubMedGoogle Scholar
  • 33 Spannagl M, Trauner A, Birg A, Frank D, Hoffmann H, Siebeek M, Lill H. Sensitive detection of the activation stale of blood coagulation in porcine DIC models by a new fibrin immunoassay. Blood Coagul Pibrinolysis 1993; 4: 103-106
    PubMedGoogle Scholar
  • 34 Halvorsen S, Skjonsberg OH, Godal HC. Thrombin treated plasma employed as a standard for determination of soluble fibrin. Thromh Res 1993; 72: 305-313
    PubMedGoogle Scholar